Comparative Pharmacology
Head-to-head clinical analysis: CHOLESTYRAMINE LIGHT versus QUESTRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLESTYRAMINE LIGHT versus QUESTRAN.
CHOLESTYRAMINE LIGHT vs QUESTRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing their enterohepatic reabsorption and increasing hepatic LDL receptor activity and cholesterol catabolism.
4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.
Questran (cholestyramine) is administered orally. The typical adult dose is 4 grams (one packet or one level scoop) once or twice daily, with a maximum of 24 grams per day. The powder should be mixed with at least 120 mL of fluid (e.g., water, juice).
None Documented
None Documented
Not applicable; cholestyramine is not absorbed systemically and has no plasma half-life; clinical effect duration reflects gastrointestinal transit time.
Not applicable; the drug is not absorbed and does not have a systemic half-life. Clinical effect persists as long as the resin remains in the gut (approximately 6-8 hours per dose).
Primarily fecal as bile acid complex; <0.05% renal excretion of unchanged drug; negligible systemic absorption.
Cholestyramine is not absorbed from the gastrointestinal tract; therefore, it is excreted entirely in the feces as the intact resin, with no renal or biliary excretion.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant